A Sequence-specific Exopeptidase Activity Test (SSEAT) for “Functional” Biomarker Discovery*S
暂无分享,去创建一个
P. Tempst | J. Villanueva | R. Robbins | K. Lawlor | Arpi Nazarian | S. Yi
[1] E. Diamandis. Oncopeptidomics: a useful approach for cancer diagnosis? , 2007, Clinical chemistry.
[2] A. Olshen,et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. , 2005, The Journal of clinical investigation.
[3] P. Budde,et al. Oncopeptidomics--a commentary on opportunities and limitations. , 2007, Cancer letters.
[4] K. Coombes,et al. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. , 2005, Journal of proteome research.
[5] P. Vincent. Blood: Textbook of Hematology , 1998 .
[6] Richard D. Smith,et al. Advances and Challenges in Liquid Chromatography-Mass Spectrometry-based Proteomics Profiling for Clinical Applications* , 2006, Molecular & Cellular Proteomics.
[7] G. Sledge,et al. Extracellular proteolysis and cancer: meeting summary and future directions. , 2003, Cancer research.
[8] J. Baron,et al. The Molecular Basis of Blood Diseases , 1994 .
[9] P. Tempst,et al. Serum Peptidome Patterns That Distinguish Metastatic Thyroid Carcinoma from Cancer-free Controls Are Unbiased by Gender and Age*S , 2006, Molecular & Cellular Proteomics.
[10] P. Tempst,et al. Lethal Effects of Apidaecin on Escherichia coliInvolve Sequential Molecular Interactions with Diverse Targets* , 1999, The Journal of Biological Chemistry.
[11] M. Mann,et al. Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics* , 2002, Molecular & Cellular Proteomics.
[12] B. Cravatt,et al. Proteomic profiling of mechanistically distinct enzyme classes using a common chemotype , 2002, Nature Biotechnology.
[13] G. Goldsmith. Hemostatic Changes in Patients with Malignancy , 2001, International journal of hematology.
[14] Dai,et al. Platelet activation. , 2020, Arteriosclerosis.
[15] R. Bick. Coagulation Abnormalities in Malignancy: A Review , 1992, Seminars in thrombosis and hemostasis.
[16] E. Diamandis. Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.
[17] J. Yates,et al. Large-scale analysis of the yeast proteome by multidimensional protein identification technology , 2001, Nature Biotechnology.
[18] S. Patterson,et al. Does the serum peptidome reveal hemostatic dysregulation? , 2007, Ernst Schering Research Foundation workshop.
[19] S. Gygi,et al. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.
[20] Leigh Anderson,et al. Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.
[21] O. Jensen. Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. , 2004, Current opinion in chemical biology.
[22] E. Petricoin,et al. The blood peptidome: a higher dimension of information content for cancer biomarker discovery , 2006, Nature Reviews Cancer.
[23] Nasreen S Jessani,et al. A streamlined platform for high-content functional proteomics of primary human specimens , 2005, Nature Methods.
[24] X. Puente,et al. Human and mouse proteases: a comparative genomic approach , 2003, Nature Reviews Genetics.
[25] P. Tempst,et al. Correcting common errors in identifying cancer-specific serum peptide signatures. , 2005, Journal of proteome research.
[26] Matthew Bogyo,et al. Activity-based probes that target diverse cysteine protease families , 2005, Nature chemical biology.
[27] Hartmut Selle,et al. The Process Chain for Peptidomic Biomarker Discovery , 2006, Disease markers.
[28] R. Silverstein,et al. Hypercoagulability in cancer. , 1996, Hematology/oncology clinics of North America.
[29] David Sidransky,et al. Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.
[30] H. Erdjument-Bromage,et al. Biodiversity of apidaecin-type peptide antibiotics. Prospects of manipulating the antibacterial spectrum and combating acquired resistance. , 1994, The Journal of biological chemistry.
[31] Massimo Pandolfo,et al. Molecular Basis , 2022 .
[32] B. Kemp,et al. Active site-directed protein regulation , 1999, Nature.
[33] B. Alberts,et al. Molecular Biology of the Cell 4th edition , 2007 .
[34] P. Marx. Thrombin-activatable fibrinolysis inhibitor. , 2004, Current medicinal chemistry.
[35] Erika Check,et al. Proteomics and cancer: Running before we can walk? , 2004, Nature.
[36] Paul Tempst,et al. Data analysis of assorted serum peptidome profiles , 2007, Nature Protocols.
[37] Bonnie F. Sloane,et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. , 2004, The American journal of pathology.
[38] R. Fisher,et al. Hemostatic abnormalities in untreated cancer: incidence and correlation with thrombotic and hemorrhagic complications. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] S. Gygi,et al. Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[40] A. Burlingame,et al. Chemical Approaches for Functionally Probing the Proteome* , 2002, Molecular & Cellular Proteomics.
[41] M. Levine,et al. Hemostatic alterations in cancer patients , 2005, Cancer and Metastasis Reviews.
[42] P. Tempst,et al. Automated serum peptide profiling , 2006, Nature Protocols.
[43] George G Klee,et al. Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-Ms/MS using protein cleavage and isotope dilution mass spectrometry. , 2004, Journal of proteome research.
[44] E. Holland,et al. Serum peptide profiling by magnetic particle-assisted, automated sample processing and MALDI-TOF mass spectrometry. , 2004, Analytical chemistry.
[45] F. Rickles,et al. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. , 1983, Blood.